Is Vertex Pharmaceuticals (VRTX) Now Offering A Compelling Entry Point After Flat One Year Returns

If you are wondering whether Vertex Pharmaceuticals' current share price gives you a fair entry point, this article will walk ...
Benzinga.com

Vertex Risk/Reward Path In Focus: 'Magnitude Of Stock Move Was Greater Than Expected'

BMO Capital Markets analyst Daniel Jester reiterated the Market Perform rating on Vertex, Inc. (NASDAQ:VERX), raising the price target to $28 from $24. Investors rewarded the consistent execution ...
Seeking Alpha

Vertex: Poised For Long-Term Growth Driven By Multiple Pipeline Catalysts

Vertex Pharmaceuticals has a strong focus on cystic fibrosis, which is driving revenue growth and pipeline development. The company has outperformed Johnson & Johnson and the S&P 500 in terms of total ...
Seeking Alpha

Vertex On Track To Significantly Improve Revenue And Earnings By 2030

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain ...
Barchart on MSN

Vertex Pharmaceuticals stock: Is Wall Street bullish or bearish?

Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology firm that discovers, develops, and commercializes ...
Nasdaq

Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...